tbuckley/cabot-search huggingface dataset:
Trends in Diagnosed and Undiagnosed Diabetes Among Adults in the U.S., 2005–2016
Authors: Peng-Fei Xia, Xiong-Fei Pan, Yue Li, Kunquan Guo, Kun Yang, Zhou-Zheng Tu, Yan-Bo Zhang, Ting-Ting Geng, Gang Liu, An Pan
Journal: Diabetes Care (2021)

Accurate surveillance of diabetes is crucial for establishing relevant policies of diabetes prevention and control. Previous studies estimated the trends in diabetes among adults in the U.S.; however, many did not consider results of the oral glucose tolerance test (OGTT) (1), and those studies that included the OGTT results reported a higher prevalence of undiagnosed diabetes (2). Capitalizing on the OGTT data since 2005–2006 in the National Health and Nutrition Examination Survey (NHANES), we assessed the trends in diagnosed and undiagnosed diabetes among adults in the U.S. from 2005 to 2016.

NHANES is a cross-sectional survey with a stratified, multistage probability design to assess the health status of the noninstitutionalized civilian population in the U.S. (3). A household interview was conducted to collect health-related information including demographic characteristics and medical history. A subset of participants was randomly selected to provide a fasting blood sample and take an OGTT at the mobile examination center. Sample weights were constructed to account for nonresponse and oversampling. The survey was approved by the research ethics review board of the National Center for Health Statistics. Written informed consent was obtained from each participant.

This investigation included nonpregnant participants aged 20 years or older, recruited from 2005–2006 to 2015–2016 cycles, who had information on self-reported diagnosed diabetes or laboratory results of fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), and 2-h plasma glucose (2-h PG). We calibrated plasma glucose measurements to …
Abstract 2883: Theranostics nanoparticles targeting to metastatic non small cell lung cancer
Authors: LI-JIE LI, Ming-Hsien Chan, Wei-Min Chang, Michael Hsiao
Journal: Cancer Research (2021)

Abstract Non-small-cell lung cancer (NSCLC) accounts for one of the most deadly cancers due to metastasis after therapy. Cancer metastasis usually results from epithelial-to-mesenchymal transition (EMT), and metabolic disorder is a key mediator of lung cancer EMT. The linkage between metabolic disorder and NSCLC EMT is still unclear. Using in silico analysis, C4ST1, a key enzyme of glycosaminoglycan synthesis pathway was up-regulation in mesenchymal type NSCLC cells. C4ST1 catalyzes chondroitin sulfate A (CsA) formation. We found both C4ST1 and CsA were up-regulation in mesenchymal type NSCLC cells. Not only C4ST1 overexpression but also CsA treatments changed NSCLC EMT balance and decreased the transcriptional activity on CDH1 promoter region. Furthermore, both treatments could promote in vitro NSCLC migration and invasion abilities in the epithelial type NSCLC cells. Up-regulation of C4ST1 cells also promoted lung cancer metastasis. Moreover, we used CsA binding peptide as a targeting ligands of metastatic NSCLC cells on theranostics nanoparticles. In summary, this study finds key gene in NSCLC EMT. Up-regulation of C4ST1 promotes NSCLC EMT and cell surface CsA content which may provide a novel theranostics niche on metastatic NSCLC cells. Citation Format: LI-JIE LI, Ming-Hsien Chan, Wei-Min Chang, Michael Hsiao. Theranostics nanoparticles targeting to metastatic non small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2883.
Concerns About Study on Fluoroquinolone Use and Risk of Development Of Aortic Aneurysm
Authors: Chao-Hsien Chen, Cheng-Yi Wang, Chih-Cheng Lai
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
An international policy on returning genomic research results
Authors: Anna C. F. Lewis, Bartha Maria Knoppers, Robert C. Green
Journal: Genome Medicine (2021)

The Global Alliance for Genomics and Health has approved a policy for the return of clinically actionable genomic research results, the first such policy approved by an international body. The policy acknowledges the potential medical benefits to millions of individuals who are participating in genomics research. It ties the pace of implementation to each country's clinical standards, including for the return of secondary findings, and urges funders to set aside resources to support responsible return.
Abstract 2462: A combination of IL7Rα and NRAS mutations up-regulates Bcl-2 and cMyc levels leading to formation of T-cell acute lymphoblastic leukemia
Authors: Hila Winer, Gisele Rodrigues, Wenqing Li, Julie Hixon, Scott K. Durum
Journal: Cancer Research (2021)

Abstract T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive leukemia derived from T-cell precursors. With current treatments, survival rate is high, but the treatments are highly toxic with severe side effects. In addition, relapse is relatively common in T-ALL and is exceptionally difficult to salvage with hematopoietic stem cell transplant which is essentially the only treatment. Thus, a better understanding of T-ALL etiology and subtypes is required to develop the warranted improved therapies. Individual mutations in IL7Rα and RAS pathways have been previously shown to be prevalent in T-ALL and especially in relapsed patients. However, it is not fully understood how these mutations are involved in disease origin and progression. In addition, we have previously shown that mutations in either IL7Rα or NRAS alone are not sufficient to induce T-ALL. Nevertheless, a combination of both causes severe T-ALL in mice which can be ameliorated by IL7Rα and NRAS signaling inhibition. To better understand how this combination can be utilized to understand disease etiology, we have tested for combinations of mutations that resulted in varying expression levels of the mutated proteins. Our results revealed that a specific ratio between IL7Rα and NRAS expression is necessary to generate T-ALL in mice. Transplanting transduced lymphocyte progenitors into RAG-/- immune-deficient mice allowed us to find an optimal order of the two oncogenes in a polycistronic vector that leads to severe T-ALL. A comparison of transplants from several arrangements of oncogenes in the vector enabled us to screen for potential regulatory pathways that are important for disease progression in vivo by analyzing the cancer cells' transcriptome and proteome. We found that the disease is characterized by a significant increase in IL7Rα-mediated BCL-2 expression, and an increase in c-Myc protein levels, via NRAS signaling. Our results are confirmed by induction of a similar phenotype with a combination of overexpressed WT c-Myc and mutant IL7Rα, which caused severe leukemia as early as 16 days post-transplant. Taken together, we developed a robust model to study T-ALL in mice, shed light on novel pathways of oncogenesis and discovered new targets for intervention that could lead to better therapeutic development. Citation Format: Hila Winer, Gisele Rodrigues, Wenqing Li, Julie Hixon, Scott K. Durum. A combination of IL7Rα and NRAS mutations up-regulates Bcl-2 and cMyc levels leading to formation of T-cell acute lymphoblastic leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2462.
Six-week behaviour change intervention to reduce sedentary behaviour in people with chronic obstructive pulmonary disease: a randomised controlled trial
Authors: Sonia Wing Mei Cheng, Jennifer Alison, Emmanuel Stamatakis, Sarah Dennis, Renae McNamara, Lissa Spencer, Zoe McKeough
Journal: Thorax (2021)

Introduction This study aimed to determine whether a 6-week behaviour change intervention was more effective than a sham intervention for reducing sedentary behaviour (SB) in people with chronic obstructive pulmonary disease (COPD). Methods People with stable COPD on the waitlist for entry into pulmonary rehabilitation were recruited to this multicentre trial with randomisation (independent, concealed allocation) to either an intervention group or sham group, assessor blinding and intention-to-treat (ITT) analysis. The behaviour change intervention consisted of once weekly sessions for 6 weeks with a physiotherapist to reduce SB through education, guided goals setting and real-time feedback on SB. The sham intervention consisted of once weekly phone calls for 6 weeks to monitor health status. SB was measured continuously over 7 days using thigh-worn accelerometry (activPAL3 micro). The primary outcome was time spent in SB. Participants with at least 4 days of ≥10 hours waking wear time were included in the ITT analysis and those who reported achieving ≥70% of goals to reduce SB or who completed all sham calls were included in a per-protocol analysis. Results 70 participants were recruited and 65 completed the study (mean±SD age 74±9 years, mean FEV 1 55%±19% predicted, 49% male). At 6 weeks, no between-group differences in time spent in SB were observed in the ITT analysis (mean difference 5 min/day, 95% CI −38 to 48) or per-protocol analysis (−16 min/day, 95% CI −80 to 48). Discussion A 6-week behaviour change intervention did not reduce time in SB compared with a sham intervention in people with stable moderate-to-severe COPD prior to pulmonary rehabilitation.
Varicocelectomy improves the sperm capacity to induce optimal embryonic and fetal development post-fertilization in a donor oocyte-surrogacy motherhood program
Authors: F. Dimitriadis, A. Kaltsas, A. Zachariou, M. Yasuyuki, S. Koukos, S. Skouros, A. Zikopoulos, I. Giannakis, A. Karagiannis, A. Paliouras, I. Giakoumakis, P. Tsounapi, D. Dafnis, A. Takenaka, N. Sofikitis
Journal: European Urology (2021)
Abstract 914: Activity of SGN-B6A in patient-derived xenograft models of non-small cell lung cancer
Authors: Robert P. Lyon, John J. Gosink, Christopher J. Hale, Jackie L. Stilwell, Sean Allred, Kelly M. Hensley, Vineet Kumar, Gabby Patilea-Vrana, Natalya Nazarenko
Journal: Cancer Research (2021)

Abstract The integrins are a large family of cell surface receptors with diverse roles in cellular adhesion, motility, and cytokinesis. Functional integrins exist as heterodimers consisting of single alpha and beta chains. Within this family, integrin beta-6, which dimerizes exclusively with isoform alpha-v, is expressed constitutively at low levels in numerous epithelial tissues and induced by tissue injury due to its role in tissue remodeling and wound repair. Numerous solid tumors, including non-small cell lung cancer (NSCLC), have been reported to overexpress integrin beta-6. Its role in tissue remodeling is believed to be the function that malignant cells exploit through its overexpression, allowing them to become more invasive into surrounding healthy tissue. Integrin beta-6 has also been reported to be among the integrins that can promote the epithelial to mesenchymal transition as well as provide resistance to anoikis, thus increasing the metastatic potential of malignant cells expressing it. SGN-B6A is an investigational antibody-drug conjugate (ADC) targeting integrin beta-6 to deliver the clinically validated payload monomethyl auristatin E (MMAE). We have previously presented data illustrating the antitumor activity of SGN-B6A in cell line-derived xenograft models originating from multiple carcinoma indications. Here we present results from a study of SGN-B6A activity dosed weekly at 3 mg/kg in patient-derived xenograft models of NSCLC, representing both squamous and adenocarcinoma histology. These results suggest that SGN-B6A is a promising ADC for the treatment of NSCLC and support further clinical investigation in the ongoing Phase I study (NCT04389632). Citation Format: Robert P. Lyon, John J. Gosink, Christopher J. Hale, Jackie L. Stilwell, Sean Allred, Kelly M. Hensley, Vineet Kumar, Gabby Patilea-Vrana, Natalya Nazarenko. Activity of SGN-B6A in patient-derived xenograft models of non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 914.
Current practices in high and low volume centers regarding corporotomy localization during penoscrotal inflatable penile implant surgery
Authors: K. Van Renterghem, B. Jacobs, F. Yafi, D. Osmonov, D. Ralph, L. Venturino, J.T. Barnard, M. Ziegelmann, R. Wang, C. Kannady, A. Lentz, E. Lledo Garcia, R. Andrianne, C. Bettochi, G. Hatzichristodoulou, M. Gross, A. Faix, J. Romero Otero, J.I. Martinez Salamanca, O. Sedigh, M. Albersen, M. Dinkelman-Smit, I. Mikoniatis
Journal: European Urology (2021)
Severe COVID-19 in patients with hematological cancers presenting with viremia
Authors: J.M. Michot, T. Hueso, N. Ibrahimi, F. Pommeret, C. Willekens, E. Colomba, S. Francis, A. Bayle, P.H. Cournède, M. Merad, S. Foulon, L. Albiges, B. Gachot, F. Barlesi, J.C. Soria, V. Ribrag, F. Griscelli
Journal: Annals of Oncology (2021)
First identification and validation of prostate cancer specific tumor endothelial cell markers by multi-omic profiling
Authors: I. Heidegger, A. Offermanns, H. Timmer-Bosscha, G. Schäfer, J. Goveia, S. Daum, A. Walenkamp, S. Perner, Z. Trajanoski, A. Krogsdam, J. Haybaeck, C. Plattner, S. Salcher, S. Thaler, M. Keller, H. Klocker, D. Wolf, A. Pircher
Journal: European Urology (2021)
非トランスフェリン結合鉄(NTBI)摂取のためのヒト肝細胞およびDMT1を過剰発現する肝癌細胞のDMT1(IRE+)の機能的役割
Authors: Torimoto Y, Shindo M, Saito H, Fujimoto Y, Iuchi Y, Shinzaki H, Watanabe S, Ohnishi K, Sato K, Kohgo Y
Journal: Blood (2001)
Comparison of Outcomes of Post-Transplant Cyclophosphamide between Haplo-Identical and Matched/Mismatched Donor Peripheral Blood Stem Cell Transplantation
Authors: Dipenkumar Modi, Seongho Kim, Abhinav Deol, Lois Ayash, Asif Alavi, Divaya Bhutani, Voravit Ratanatharathorn, Joseph P. Uberti
Journal: Blood (2017)
Abstract 1523: A Novel <i>SCN5A</i> Gain-of-Function Mutation M1875T Associated with Familial Atrial Fibrillation
Authors: Takeru Makiyama, Masaharu Akao, Satoshi Shizuta, Takahiro Doi, Kei Nishiyama, Oka Yuko, Yukiko Nishio, Keiko Tsuji, Hideki Itoh, Takeshi Kimura, Toru Kita, Minoru Horie
Journal: Circulation (2008)

Background: Mutations in the cardiac sodium (Na + ) channel gene, SCN5A , have been associated with a variety of inherited arrhythmias, but the gain-of-function type modulation in SCN5A is associated with only one phenotype, long-QT syndrome type3 (LQTS3). Methods and Results: We studied a Japanese family with autosomal dominant hereditary atrial fibrillation (AF), multiple members of which showed onset of AF or frequent premature atrial contractions at a young age. The 31-year-old proband received radio-frequency catheter ablation, during which time numerous ectopic firings and increased excitability throughout the right atrium were documented. Mutational analysis identified a novel missense mutation, M1875T, in SCN5A . Further investigations revealed the aggregation of this mutation in all of the affected individuals (Figure A ). Functional assays of the M1875T Na + channels using whole-cell patch-clamp demonstrated a distinct gain-of-function type modulation; a pronounced depolarized shift (+16.4 mV) in V 1/2 of the voltage dependence of steady-state inactivation (Figure B ), and no late Na + current which is a defining mechanism of LQTS3. These biophysical features of the mutant channels are potentially associated with increased atrial excitability and normal QT interval in all of the affected individuals. Conclusions: We identified a novel SCN5A mutation associated with familial AF. The mutant channels displayed a gain-of-function type modulation of cardiac Na + channels, which is a novel mechanism predisposing increased atrial excitability and familial AF. This is a new phenotype resulting from the SCN5A gain-of-function mutations and is distinct from LQTS3.
Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma
Authors: Jiaying Wu, Fankai Meng, Yang Cao, Yicheng Zhang, Xiaojian Zhu, Na Wang, Jue Wang, Lifang Huang, Jianfeng Zhou, Yi Xiao
Journal: Blood Cancer Journal (2021)

Abstract Chimeric antigen receptor (CAR) T-cell immunotherapy following autologous stem cell transplantation (ASCT) is a promising method for refractory or relapsed multiple myeloma, but explicit data for central nervous system lymphoma (CNSL) are lacking. Here, we treated 13 CNSL patients with ASCT sequential CD19/22 CAR T-cell infusion and simultaneously evaluated the clinical efficacy and toxicity. The 13 CNSL patients analyzed included four primary CNSL and nine secondary CNSL patients. Patients 1 and 10, who had complete remission status before enrollment, maintained clinical efficacy without recurrence. Nine of the remaining 11 patients responded to our protocol with a median durable time of 14.03 months, and the overall response and complete remission rate were 81.81% and 54.55%, respectively. No patient suffered grades 3–4 cytokine-release syndrome (CRS), and only patient 10 experienced severe immune effector cell-associated neurotoxicity syndrome (ICANS). In addition, increases in serum ferritin and interleukin-6 levels were often accompanied by CRS and ICANS. After a median follow-up time of 14.20 months, the estimated 1-year progression-free survival and overall survival rates were 74.59% and 82.50%, respectively. Sequential CD19/22 CAR T-cell immunotherapy following ASCT as a novel method for CNSL appears to have encouraging long-term efficacy with relatively manageable side effects.
Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis
Authors: Joan Clària, Anna Curto, Richard Moreau, Benoit Colsch, Cristina López-Vicario, Juan José Lozano, Ferran Aguilar, Florence A. Castelli, François Fenaille, Christophe Junot, Ingrid Zhang, Maria Vinaixa, Oscar Yanes, Paolo Caraceni, Jonel Trebicka, Javier Fernández, Paolo Angeli, Rajiv Jalan, Vicente Arroyo
Journal: Journal of Hepatology (2021)

Acute decompensation (AD) of cirrhosis is a heterogeneous clinical entity associated with moderate mortality. In some patients, this condition develops quickly into the more deadly acute-on-chronic liver failure (ACLF), in which other organs such as the kidneys or brain fail. The aim of this study was to characterize the blood lipidome in a large series of patients with cirrhosis and identify specific signatures associated with AD and ACLF development.Serum untargeted lipidomics was performed in 561 patients with AD (518 without and 43 with ACLF) (discovery cohort) and in 265 patients with AD (128 without and 137 with ACLF) in whom serum samples were available to perform repeated measurements during the 28-day follow-up (validation cohort). Analyses were also performed in 78 patients with AD included in a therapeutic albumin trial (43 patients with compensated cirrhosis and 29 healthy individuals).The circulating lipid landscape associated with cirrhosis was characterized by a generalized suppression, which was more manifest during AD and in non-surviving patients. By computing discriminating accuracy and the variable importance projection score for each of the 223 annotated lipids, we identified a sphingomyelin fingerprint specific for AD of cirrhosis and a distinct cholesteryl ester and lysophosphatidylcholine fingerprint for ACLF. Liver dysfunction and infections were the principal net contributors to these fingerprints, which were dynamic and interchangeable between patients with AD whose condition worsened to ACLF and those who improved. Notably, blood lysophosphatidylcholine levels increased in these patients after albumin therapy.Our findings provide insights into the lipid landscape associated with decompensation of cirrhosis and ACLF progression and identify unique non-invasive diagnostic biomarkers of advanced cirrhosis.Analysis of lipids in blood from patients with advanced cirrhosis reveals a general suppression of their levels in the circulation of these patients. A specific group of lipids known as sphingomyelins are useful to distinguish between patients with compensated and decompensated cirrhosis. Another group of lipids designated cholesteryl esters further distinguishes patients with decompensated cirrhosis who are at risk of developing organ failures.
Measurement of urinary Dickkopf-3 uncovered silent progressive kidney injury in patients with chronic obstructive pulmonary disease
Authors: Stefan J. Schunk, Christoph Beisswenger, Felix Ritzmann, Christian Herr, Martina Wagner, Sarah Triem, Gregor Hütter, David Schmit, Stephen Zewinger, Tamim Sarakpi, Anja Honecker, Peer Mahadevan, Peter Boor, Stefan Wagenpfeil, Rudolf Jörres, Henrik Watz, Tobias Welte, Claus F. Vogelmeier, Hermann-Josef Gröne, Danilo Fliser, Thimoteus Speer, Robert Bals
Journal: Kidney International (2021)
Validation of the TORSAFUF score in diagnosis of spermatic cord torsion: A French multicenter study
Authors: C. Plassais, I. Bentellis, U. Pinar, I. Duquesne, M. Felber, V.T. Dang, N. Ali Benali, W. Berchiche, C. Gaillard, A. Mauger De Varennes, G. Margue, F. Bardet, M. Hulin, A. Manuguerra, W. Wandoren, M. Chabenes, M. Sbizerra, V. Gaillard, X. Matillon, F. Lannes, Z.E. Khene, B. Pradère
Journal: European Urology (2021)
Prognostic impact of different Gleason patterns within grade group 4 prostate cancer in radical prostatectomy specimens
Authors: K. Mori, V. Sharma, E.M. Comperat, E. Laukhtina, V.M. Schuettfort, B. Pradere, R. Sari Motlagh, H. Mostafaei, F. Quhal, S. Katayama, S. Egawa, D. Tilki, S.A. Boorjian, S.F. Shariat
Journal: European Urology (2021)